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VANCOMYCIN RESISTANT ENTEROCOCCUS (VRE) BLOODSTREAM IN-
FECTIONS (BSI) IN PATIENTS WITH MALIGNANT HEMATOLOGICAL
DISORDERS: IS THE SICK GETTING SICKER?
Dubberke, E.R.1, DiPersio, J.F.1, Mundy, L.1, Khoury, H.J.2 1. Wash-
ington University School of Medicine, St. Louis, MO; 2. Emory Uni-
versity Scool of Medicine, Atlanta, GA.
Patients with hematologic malignancies and hematopoietic stem
cell transplant (HSCT) recipients are at high risk for bacterial BSI.
Data describing the prognosis and outcomes of VRE BSI in this
patient population is limited. We performed a retrospective chart
review of all cases of VRE BSI occurring between February 1996
and December 2002 on the Leukemia/HSCT unit at Barnes-
Jewish Hospital. Sixty-eight episodes of VRE BSI were observed in
60 patients with acute (53%) or chronic (8%) leukemia, NHL
(22%), or other malignant hematologic disorders (17%). Thirteen
percent, 32%, and 32% were recipients of autologous, related, and
VUD transplant, respectively. Forty days prior to the VRE BSI,
70% were colonized with VRE, 95% had broad-spectrum antibi-
otic exposure and 42% had non-VRE BSI, 35% pneumonia, 22%
CMV reactivation, 10% fungal infection. At the time of the VRE
BSI, 42% of allograft recipients had active acute GVHD and 32%
chronic GVHD. Only 57% were neutropenic, 52% had refractory/
relapsed malignancy, and 60% had end organ dysfunction with a
median APACHE II score of 17. VRE was easily eradicated from
the bloodstream after initiation of anti-VRE therapy (median time
to clearance 1 (range 1–9) days). Three patients died within 48
hours of the VRE BSI from causes unrelated to the BSI. Median
survival after VRE BSI was 19 days. Only 4 deaths were directly
attributable to the VRE BSI. Age, ECOG PS  2 on admission,
HSCT, pneumonia, mechanical ventilation, acute neurologic dys-
function, receipt of anti-fungal drugs, and low APACHE II score
were signiﬁcant factors associated with death by univariate analysis,
while pneumonia, receipt of anti-fungal drugs, and low APACHE
II score at the time of the VRE BSI remained signiﬁcant after
multivariate analysis. In summary, our analysis suggests that in
patients with hematological malignancies, VRE does not have the
microbiologic behavior of a virulent pathogen and that VRE BSI
may simply be a marker of these patients’s already existing critical
medical condition.
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IMPACT OF NEUTRALIZING ANTIBODY TO RESPIRATORY SYNCYTIAL
VIRUS (RSV) ON RESPIRATORY DISEASE PROGRESSION IN HEMATO-
POIETIC STEM CELL TRANSPLANT RECIPIENTS (HCT)
Englund, J.A.1,2, Walsh, E.3, Falsey, A.3, Kim, H.1, Corey, L.1,4,
Boeckh, M.1,4 1. Fred Hutchinson Cancer Research Center, Seattle, WA;
2. Children’s Hospital and Regional Medical Center, Seattle, WA; 3.
Univ. Rochester, Rochester, NY; 4. University of Washington, Seattle,
WA.
RSV-speciﬁc antibody is important in preventing severe RSV
disease in young children when given prophylactically, but the
importance of RSV-speciﬁc antibody (Ab) in preventing progres-
sion of RSV disease during HCT is not known. We prospectively
collected serum in HCT recipients and their donors pre- and in
recipients during transplant (Tx). Symptomatic patients were eval-
uated with nasal wash if symptoms of upper tract respiratory tract
infection (URI) were noted; patients with evidence of respiratory
distress, oxygen requirement, or radiographic changes, and detec-
tion of RSV in the lower airways were determined to have lower
respiratory tract infection (LRI). RSV-speciﬁc neutralizing Ab was
retrospectively measured using standard microneutralization as-
says. Sixty-two HCT recipients diagnosed with RSV infection
were evaluated; 25 (40%) had RSV diagnosed within the ﬁrst 30
days postTx. Subsequently, 39 patients (67%) had URI disease
which progressed to lower respiratory tract infection (LRI). Pro-
gression occurred in 13/25 (48%) of patients diagnosed at 30
days postTx compared with 11/37 (30%) of those with RSV at	30
days postTx. Ab levels obtained in HCT two weeks prior to the
time RSV infection was diagnosed did not appear to protect pa-
tients from more serious RSV disease: mean log2 antibody level
two weeks prior to diagnosis was 10.2 for patients who developed
RSV-related URI compared with levels of 9.7 in patients who
progressed to LRI (P  .10). Controlling for lymphopenia, higher
Ab levels in donors also did not appear to protect from the devel-
opment of LRI in Tx recipients. However, Ab levels in HCT
recipients after 	30 days postTX did appear to prevent RSV
disease progression: the mean log2 Ab levels in 27 HCT recipients
with RSV after 	30 days postTx was 10.5 (95% CI, 9.3–11.4) in
URI patients vs 9.3 (95% CI, 8.6–10.6) in LRI patients, P  .04.
These results suggest that RSV-speciﬁc neutralizing Ab may con-
tribute to the prevention of RSV disease progression in HCT
recipients later postTX.
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LONGITUDINAL ASSESSMENT OF QUALITY OF LIFE AND SYMPTOMS OF
ETHNICALLY DIVERSE BLOOD AND MARROW TRANSPLANTATION PA-
TIENTS
Neumann, J.L.1, Cohen, M.Z.2, Mendoza, T.R.1, Gning, I.1,
Aleman, A.S.1, Giralt, S.1, Cleeland, C.S.1 1. University of Texas MD
Anderson Cancer Center, Houston, TX; 2. University of Texas School of
Nursing, Houston, TX.
Studies that have examined the effects of BMT on quality of life
(QOL) have found a signiﬁcant reduction in QOL and persistent
symptoms of fatigue, insomnia, anorexia, and nausea in the ﬁrst
year after BMT (Kopp, Schweigkoﬂer, Holzner, et al 1998, Winer,
Lindley, Hardee, et al 1999, Hann, Jacobsen, Martin, et al 1997).
The long-term impact of BMT on quality of life has also been
examined (Andrykowski, Carpenter, et al 1997, Andrykowski,
Brady, et al 1995 and Andrykowski, Bishop, Hahn, Cella, et al,
2005). None of these studies examined differences of quality of life
and symptoms among ethnically diverse patients. In our recently
completed National Institute of Health sponsored study, the cor-
relation of quality of life and symptoms was evaluated at multiple
time points over the course of 100 days in 164 patients, including
African-Americans (n  24), Hispanics (n  38) and non-minority
(n  102) patients. Data collected included the Functional Assess-
ment of Cancer Therapy (FACT-BMT) measuring quality of life
and MD Anderson Symptom Inventory (MDASI) assessing symp-
toms and symptom interference with life. Other variables examined
included disease, type of transplant, age, graft-versus-host disease
(GVHD) and survival. Preliminary results indicate that patients
receiving myeloablative regimen experienced severe symptoms
such as fatigue (P  .02) and pain (P  .03) and poorer quality of
life (P  .01) across time. Symptom severity correlated (r  .59 to
.75) with quality of life across time. In addition, there were no
signiﬁcant differences in symptom severity, symptom interference
and ECOG performance status among the 3 ethnic groups over
time. There were signiﬁcant differences in symptom severity,
symptom interference, and ECOG performance across time com-
paring minority and non-minority BMT patients. This project,
Symptom Management in Blood and Marrow Transplantation,
was funded by grant no.1 RO1 NR05188-01A2, funded by Na-
tional Institutes of Health, National Institute of Nursing Research,
to Principal Investigator Marlene Zichi Cohen.
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LONG TERM SUPPRESSIVE ACYCLOVIR (ACV) REDUCES VZV DISEASE
AND ACV-RESISTANT HSV AFTER HCT
Erard, V.1, Wald, A.1, Leisenring, W.1, Varley, C.1, Heugel, J.1,
Corey, L.1, Boeckh, M.1 Fred Hutchinson Cancer Research Center and
the University of Washington, Seattle, WA.
Background: Acyclovir given for 1 year prevents reactivation
VZV disease during the ﬁrst year after HCT, but the risk persists
after the ﬁrst year in patients with continued need for immuno-
suppressive drugs (Boeckh et al Blood, in press). The purpose of
this study was to determine the efﬁcacy of 2 sequentially intro-
duced long-term suppressive ACV regimens at the FHCRC.
Methods: Three cohorts of VZV seropositive recipients were
examined: cohort 1 (no ACV; before 1999, n  932), cohort 2
(ACV 800 mg or VACV 500 mg BID for 1 year; 1999–2002; n 
1117), and cohort 3 (ACV/VACV as in cohort 2 plus extended use
in patients who were still taking immunosuppressive drugs at 1
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year; 2002–2003, n  402). The crude incidence rates of the ﬁrst
VZV disease episode in the 3 cohorts were calculated at 1 year and
at 2 years after HCT. Multivariable Cox proportional hazard
models were used to assess the effect of ACV. In addition, we
examined the effect of long-term ACV on the incidence of ACV-
resistant HSV infection. Results: At 1 year after HCT, VZV
disease decreased from 34 per 100 person-years in cohort 1 to 4.9
in cohort 2 (P  .001) and 1.7 in cohort 3 (P  .001). The
difference persisted by 2 years (27, 7.6, 3.8 per 100 person-years,
respectively, [all comparisons P .01]). Compared to cohort 1, the
adjusted hazard ratio (HR) of developing the ﬁrst episode of VZV
disease was 0.15 (P  .001) in cohort 2 and 0.05 (P  .001) in
cohort 3 by 1 year; by 2 years the adjusted HRs were 0.30 (P 
.001) and 0.15 (P  .001), respectively. To assess the effect of
extending ACV beyond 1 year, cohorts 2 and 3 were compared and
showed a trend toward a reduced risk of VZV in cohort 3 by 2 years
(HR 0.60, P  .07). All breakthrough VZV cases responded to
treatment with ACV or Valacyclovir. During the study, 10 epi-
sodes of ACV-resistant HSV occurred in cohort 1 and 2 episodes
in cohorts 2 and 3 combined (P  .001). Conclusions: Long-term
suppressive ACV prophylaxis sharply reduces the incidence of
VZV disease during the ﬁrst year after HCT with no detectable
rebound disease after discontinuation of prophylaxis. Continuation
of ACV beyond 1 year in patients on immunosuppressive drugs
may further decrease the risk of VZV disease. Suppressive acyclovir
decreases the risk of ACV-resistant HSV infection.
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A MULTICENTER, RANDOMIZED TRIAL OF POSACONAZOLE (POS) VS
FLUCONAZOLE (FLU) OR ITRACONAZOLE (ITZ) FOR PROPHYLAXIS OF
INVASIVE FUNGAL INFECTIONS (IFIs) IN NEUTROPENIC PATIENTS
WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR MYELODYSPLASTIC
SYNDROME (MDS) RECEIVING INTENSIVE CHEMOTHERAPY
Winston, D.J.1, Cornely, O.A.2, Maertens, J.3, Perfect, J.4,
Helfgott, D.5, Ullmann, A.J.6, Holowiecki, J.7, Stockelberg, D.8,
Goh, Y.-T.9, Petrini, M.10, Walsh, T.J.11, Hardalo, C.12,
Angulo-Gonzalez, D.12 1. University of California, Los Angeles, CA; 2.
University of Cologne, Cologne, Germany; 3. University Hospital Gas-
thuisberg, Leuven, Belgium; 4. Duke University Hospital, Durham,
NC; 5. Weill Medical College of Cornell University, New York, NY; 6.
Johannes Gutenberg University, Mainz, Germany; 7. Silesian Medical
Academy, Katowice, Poland; 8. Sahlgrenska University Hospital, Goth-
enburg, Sweden; 9. Singapore General Hospital, Singapore; 10. Hospital
Santa Chiara, Pisa, Italy; 11. National Cancer Institute, Bethesda, MD;
12. Schering-Plough Research Institute, Kenilworth, NJ.
Introduction: Patients with severe and prolonged neutropenia
are at high risk for IFIs. Despite current treatment options, IFIs are
difﬁcult to treat and are associated with high mortality rates.
Antifungal prophylaxis is often used in high-risk neutropenic pa-
tients. We compared POS, an extended-spectrum triazole, to stan-
dard azoles (FLU or ITZ) for prevention of IFIs in patients with
new diagnosis or ﬁrst relapse of AML or MDS undergoing inten-
sive chemotherapy. Methods: Patients in this evaluator-blinded,
active-controlled, multicenter study were randomized to oral POS
suspension 200 mg tid or oral standard azole therapy (FLU 400 mg
qd or ITZ solution 200 mg bid) with each cycle of chemotherapy
until complete remission or for up to 12 weeks. Incidence of IFI
adjudicated by a blinded expert panel (by EORTC/MSG criteria)
was compared at end of treatment phase (primary endpoint) and
100 days postrandomization. Clinical outcome (treatment success
or failure), overall and attributable mortality, and Kaplan-Meier
analysis of time to death were also assessed. Treatment failure was
deﬁned as: proven/probable IFI; 	3 days empiric systemic anti-
fungal therapy; 	3 consecutive days or total of 10 days IV study
drug (or alternative formulation for POS); discontinuation due to
treatment-related AE; or lost to follow-up during treatment. Re-
sults: 602 patients were enrolled: 304 POS and 298 standard azole
(240 FLU, 58 ITZ). POS was superior to standard azole therapy
(FLU or ITZ) in preventing proven/probable IFIs during treat-
ment phase and 100 days postrandomization (Table). Overall mor-
tality was 49 (16%) versus 67 (22%) for patients in the POS and
standard azole arms, respectively. Kaplan-Meier analysis of time to
death (all-cause mortality) within 100 days postrandomization in-
dicated a signiﬁcant survival beneﬁt with POS (P  .035). Signif-
icantly fewer deaths were associated with IFIs in the POS arm (n
5) versus the standard azole arm (n  16; P  .012). Fewer
treatment failures occurred in the POS arm (36% vs 46%; P 
.0091). Safety and tolerability of POS and standard azoles were
comparable. Conclusions: In high-risk neutropenic patients with
AML or MDS undergoing intensive chemotherapy, POS was su-
perior to standard azole therapy (FLU or ITZ) in preventing
aspergillosis and IFIs overall. POS prophylaxis conferred a signif-
icant survival beneﬁt vs standard azole therapy. Safety and tolera-
bility were comparable between treatment arms (Table1).
Table 1.
Proven/Probable IFIs
POS FLU/ITZ
P Value
95.13%
Confidence
Interval (%)
(n  304) (n  298)
n (%) n (%)
All IFIs during treatment
phase*
7 (2) 25 (8) .0009 9.68 to 2.50
Aspergillus during
treatment phase
2 (1) 20 (7) .0001 9.05 to 3.05
All IFIs within 100 days
postrandomization
14 (5) 33 (11) .0031 10.76 to 2.17
*Treatment phase period from randomization to 7 days after last
dose of study drug.
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RECURRENT CYTOMEGALOVIRUS INFECTION AFTER ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION IN TAIWAN: A SINGLE
INSTITUTIONAL EXPERIENCE
Wu, S.-J.1, Lin, C.-H.2, Yao, M.2, Tang, J.-L.2 1. Far-East Memorial
Hospital, Taipei, Taiwan; 2. National Taiwan University Hospital,
Taipei, Taiwan.
Background: In Taiwan, the cytomegalovirus(CMV) sero-posi-
tive rate is 	90% in the adult population. The risk of recurrent
CMV infection and CMV-associated disease may thus be higher
after allo-geneic hematopoietic stem cell transplantation (allo-
HSCT) than in Western countries. Methods: From December
1999 to December 2004, sequential monitoring of CMV antigen-
emia was performed in 186 consecutive adult patients after allo-
HSCT till day 100. CMV antigenemia was detected by pp65
antigen assay and was deﬁned as 1 positive cells/2  105 leuko-
cytes. Statistical analysis was performed to correlate the occurrence
of CMV antigenemia with clinical characteristics, transplant
events, and outcome. Results: The cumulative probability of
CMV antigenemia at day 100 was 48.7% (median onset time at
day 36): 42.5% in matched sibling donors and 81.7% in unre-
lated/HLA-mismatched donors (log rank test, P  .0001). Identi-
ﬁed risk factors by Cox regression model analysis included elder
patient age(	40 years), use of antithymocyte globulin (ATG),
steroid treatment and administration of post-engrafment gancyclo-
vir prophylaxis. CMV antigenemia was associated with increased
risk of colitis (8.9% vs 1.1%, P .015) and interstitial pneumonitis
(14.8% vs 3.2%, P  .007). Twelve patients died of CMV-related
mortality. Detection of CMV antigenemia was correlated with
signiﬁcantly inferior 1-year overall survival (38% vs 67%, P 
.0001), especially in patients transplanted at standard disease risk
stages (55% vs 91%, P  .0001), as well as 4-year overall survival
(26% vs 50%, P  .001). Post-engraftment universal ganciclovir
prophylaxis, although was effective in preventing CMV antigen-
emia, did not lead to better overall survival. Conclusions: Recur-
rent CMV infection occurred frequently after allo-HSCT and was
associated with high morbidity and mortality. Universal prophy-
laxis did not improve the overall survival in high risk patients.
Frequent monitoring of CMV status and early preemptive anti-
viral therapy was warranted in this high risk transplant group.
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